Alterity surges after mid-stage trial data for lead asset
Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a ...
Hosted on MSN5h
PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit
PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using ...
Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
The Taipei Times15h
Keep active to stay healthy during holiday, doctors say
People should stand up and move around often while traveling or playing mahjong during the Lunar New Year holiday, as ...
Biogen (BIIB) Gets a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Taiwan News1h
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with ...